Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

BACKGROUND: Targeted therapies for triple-negative breast cancer (TNBC) are limited; however, the epidermal growth factor receptor (EGFR) represents a potential target, as the majority of TNBC express EGFR. The purpose of these studies was to evaluate the effectiveness of two EGFR-targeted antibody-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zoeller, Jason J., Vagodny, Aleksandr, Daniels, Veerle W., Taneja, Krishan, Tan, Benjamin Y., DeRose, Yoko S., Fujita, Maihi, Welm, Alana L., Letai, Anthony, Leverson, Joel D., Blot, Vincent, Bronson, Roderick T., Dillon, Deborah A., Brugge, Joan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708921/
https://www.ncbi.nlm.nih.gov/pubmed/33256808
http://dx.doi.org/10.1186/s13058-020-01374-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708921/
https://www.ncbi.nlm.nih.gov/pubmed/33256808
http://dx.doi.org/10.1186/s13058-020-01374-8

Ejemplares similares